Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026

Praxis Precision Medicines, Inc. soars after study success and pipeline wins. Explore key milestones, projections, and ...
Yahoo Finance

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Seeking Alpha

Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts

I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...
Nasdaq

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...